FGF23 and chronic kidney disease: After adding the FGF-23 inhibitor bone matrix acidic protein DMP1 into the CKD mice, the left ventricular wall thickness in the DMP1 group was significantly reduced compared with that in the CKD group (Dussold et al., 2019).